» Articles » PMID: 38804779

Follow-up to Adolescence After Early Peanut Introduction for Allergy Prevention

Abstract

Background: A randomized trial demonstrated consumption of peanut from infancy to age 5 years prevented the development of peanut allergy. An extension of that trial demonstrated the effect persisted after 1 year of peanut avoidance. This follow-up trial examined the durability of peanut tolerance at age 144 months after years of ad libitum peanut consumption.

Methods: Participants from a randomized peanut consumption trial were assessed for peanut allergy following an extended period of eating or avoiding peanuts as desired. The primary end point was the rate of peanut allergy at age 144 months.

Results: We enrolled 508 of the original 640 participants (79.4%); 497 had complete primary end point data. At age 144 months, peanut allergy remained significantly more prevalent in participants in the original peanut avoidance group than in the original peanut consumption group (15.4% [38 of 246 participants] vs. 4.4% [11 of 251 participants]; P<0.001). Participants in both groups reported avoiding peanuts for prolonged periods of time between 72 and 144 months. Participants at 144 months in the peanut consumption group had levels of Ara h2-specific immunoglobulin E (a peanut allergen associated with anaphylaxis) of 0.03 ± 3.42 kU/l and levels of peanut-specific immunoglobulin G4 of 535.5 ± 4.98 μg/l, whereas participants in the peanut avoidance group had levels of Ara h2-specific immunoglobulin E of 0.06 ± 11.21 kU/l and levels of peanut-specific immunoglobulin G4 of 209.3 ± 3.84 μg/l. Adverse events were uncommon, and the majority were related to the food challenge.

Conclusions: Peanut consumption, starting in infancy and continuing to age 5 years, provided lasting tolerance to peanut into adolescence irrespective of subsequent peanut consumption, demonstrating that long-term prevention and tolerance can be achieved in food allergy. (Funded by the National Institute of Allergy and Infectious Diseases and others; ITN070AD, ClinicalTrials.gov number, NCT03546413.).

Citing Articles

Zéro allergie research clinic: a clinical and research initiative in oral immunotherapy for managing IgE-mediated food allergy.

Tremblay B, Begin P, Gagnon-Brassard F, Boucher-Lafleur A, Lavoie M, Madore A Allergy Asthma Clin Immunol. 2024; 20(1):59.

PMID: 39488713 PMC: 11531141. DOI: 10.1186/s13223-024-00921-8.


Innate lymphoid cells in immunoglobulin E-mediated food allergy.

Ilangovan J, Neves J, Santos A Curr Opin Allergy Clin Immunol. 2024; 24(5):419-425.

PMID: 39132724 PMC: 11356679. DOI: 10.1097/ACI.0000000000001018.


Oral tolerance to dietary antigens and Foxp3 regulatory T cells.

Miranda-Waldetario M, Curotto de Lafaille M Immunol Rev. 2024; 326(1):8-16.

PMID: 39054615 PMC: 11436310. DOI: 10.1111/imr.13370.